Related Experiment Videos

Modifying the specificity and activity of the Enterobacter cloacae P99 beta-lactamase by mutagenesis within an M13

N O Siemers1, D E Yelton, J Bajorath

  • 1Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121, USA. siemers@bms.com

Biochemistry
|February 20, 1996
PubMed

Insights

Mutating key residues in Enterobacter cloacae P99 beta-lactamase altered substrate specificity and activity. This research is vital for developing novel enzyme-prodrug therapies for targeted cancer treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Enzyme kinetics

Background:

  • Enterobacter cloacae P99 beta-lactamase is crucial for antibiotic resistance.
  • Residues 286-290 in the active site are hypothesized to interact with cephalosporin 3' substituents.
  • Understanding these interactions can inform the design of targeted therapies.

Purpose of the Study:

  • To investigate the role of residues 286-290 in beta-lactamase substrate binding and catalysis.
  • To characterize mutants with altered specificities and activities for 3'-substituted cephalosporins.
  • To assess the relevance of kinetic variations in enzyme-prodrug cytotoxicity assays.

Main Methods:

  • Random mutagenesis using hybridization mutagenesis in an M13 phage vector.
  • Enrichment of active beta-lactamase genes by antibiotic selection.
  • Michaelis-Menten kinetic analyses with various cephalosporin substrates.

Main Results:

  • All five amino acid positions (286-290) were permissive to substitution, with active mutants maintaining structural integrity.
  • Serine 287 substitutions required small, uncharged residues for catalytic activity.
  • Kinetic parameters (k(cat), K(m), k(cat)/K(m)) varied significantly across mutants.

Conclusions:

  • Residues 286-290 play a significant role in the catalytic activity and substrate specificity of Enterobacter cloacae P99 beta-lactamase.
  • Mutant kinetic variations are relevant for enzyme-prodrug approaches, particularly in cytotoxicity assays with cephalosporin-doxorubicin prodrugs.
  • This study provides a foundation for optimizing enzyme kinetics in targeted cancer therapy.

Related Concept Videos